SENTINEL COHORT:
The DEE2012 “KAYAK” study will enroll in two parts: a Sentinel Cohort of 8 participants and a Main Cohort of up to 52 participants. There will be a pause in participants screening and enrollment for data analysis by an independent data monitoring committee (DMC) and any needed protocol amendments following the full enrollment of the Sentinel Cohort. |
To learn more about this study, you or your doctor may contact the study research staff:
Neurocrine Medical Information Call Center 877-641-3461 medinfo@neurocrine.com ClinicalTrials.gov identifier (NCT number): NCT04873869 |
Recruiting
Cook Children's Hospital—Fort Worth, TX Cook Children's Medical Center Fort Worth, Texas, United States, 76104 Contact: Dianna Grado, 682-885-2844 Dianna.grado@cookchildrens.org University of California San Francisco—San Francisco, CA UCSF Medical Center San Francisco, California, United States, 94158 Contact: Lucy Liu, 415-353-2437 Lucy.liu3@ucsf.edu Children's National—Washington, DC Children's National Hospital Washington, District of Columbia, United States, 20010 Contact: Zachary Kramer zkramer@childrensnational.org Children's Hospital of Philadelphia—Philadelphia, PA Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Contact: Jennie Minnick ENGIN@chop.edu |
University of Rochester—Rochester, NY
University of Rochester Rochester, New York, United States, 14642 Contact: Noreen Connolly Noreen_Connolly@urmc.rochester.edu Ann & Robert H. Lurie Children's Hospital of Chicago—Chicago, IL Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States, 60611 Contact: Enrique Rojas erojas@luriechildrens.org Not Yet Recruiting Wake Forest Baptist Health—Winston-Salem, NC Wake Forest Baptist Health Winston-Salem, North Carolina, United States, 27157 Contact: Carolyn Hedrick cwhedric@wakehealth.edu University of Utah—Salt Lake City, UT University of Utah Salt Lake City, Utah, United States, 84132 Contact: Carly Straley clinicaltrialsoffice@hsc.utah.edu |
The EMBOLD Study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric patients age 2-18 with DEEs, followed by an open-label extension.
PRAX-562 is a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in early onset SCN2A-DEE and SCN8A-DEE. |
To learn more about this study, you or your doctor may contact the study research staff:
Head of Pharmacovigilance 617-300-8460 clinicaltrials@praxismedicines.com ClinicalTrials.gov identifier (NCT number): NCT05818553 |
Kayak Study Update: September 2022
|
Embold Study Update: September 2022
|
Kayak Study Update: April 2023 (update at 5:30 mark)
|
Embold Study Update: April 2023
|
Past Annual Reports
Past PCDH19 Efforts Privacy Policy The Cute Syndrome Foundation PO Box 842 Ozark, MO 65721 |
The Cute Syndrome is registered as a tax-exempt organization under IRS section 501(c)(3).
Our tax identification number is: 46-2699066. © The Cute Syndrome Foundation, All rights reserved |